Riboflavin-Vancomycin Conjugate Enables Simultaneous Antibiotic Photo-Release and Photodynamic Killing against Resistant Gram-Positive Pathogens

This dataset was used in the analysis of a new light-activated molecule, VanB2, based on conjugation of the FDA-approved photosensitizer riboflavin to the Gram-positive specific ligand vancomycin for targeted antimicrobial photodynamic therapy. The riboflavin-vancomycin conjugate proved to be a potent and versatile antibacterial agent, enabling the rapid, light-mediated, killing of MRSA and VRE with no significant off-target effects. The attachment of riboflavin on vancomycin also led to an increased in antibiotic activity against S. aureus and VRE. Simultaneously, we evidenced that the flavin sub-unit undergoes an efficient photo-induced bond cleavage reaction to release vancomycin, thereby acting as a photo-removable protecting group for drug-delivery. This dataset is related to the upcoming article "Riboflavin-Vancomycin Conjugate Enables Simultaneous Antibiotic Photo-Release and Photodynamic Killing against Resistant Gram-Positive Pathogens" by B. Mills, A. Kiang, S. M. P. C. Mohanan, M. Bradley, K. Dhaliwal and M. Klausen (submitted to ChemRxiv).